RANI
HealthcareRani Therapeutics Holdings, Inc.
$1.36
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Rani Therapeutics Holdings, Inc. is a healthcare company in the biotechnology industry, with a market capitalization of $166.80M and approximately 105 employees. The company operates within the broader healthcare sector. Financially, Rani Therapeutics has reported a net income of -$28.32 million on revenue of $1.20 million for the trailing twelve months (TTM). The company's profitability is marked by gross margin of 100.0%, operating margin of -3418.2%, and profit margin of 0.0%. In terms of returns, Rani Therapeutics has a return on assets (ROA) of -95.5%. On the balance sheet side, the company reports $4.14 million in cash and $17.55 million in debt. Rani Therapeutics' valuation metrics include a price-to-sales ratio of 139.00 and an EV/EBITDA ratio of -3.54. The forward P/E ratio is -4.29, while the price to book ratio is -8.29.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Visit website →Key Statistics
- Market Cap
- $166.80M
- P/E Ratio
- N/A
- 52-Week High
- $3.87
- 52-Week Low
- $0.39
- Avg Volume
- 19.30M
- Beta
- 0.44
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 105